Moomoo AI 已提取核心信息
On January 18, 2024, NexImmune, Inc. held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting did not reach a quorum as per the company's Amended and Restated Bylaws, with only 331,696 shares represented. Consequently, the meeting was adjourned without conducting any business, to allow more time for stockholders to vote and to achieve the required quorum. The adjourned meeting is scheduled to reconvene virtually on February 7, 2024. The record date for stockholder determination remains November 6, 2023, and those who have already voted do not need to take further action. The company's definitive proxy statement was filed with the SEC on November 20, 2023, and no changes have been made to the proposals since. NexImmune is...Show More
On January 18, 2024, NexImmune, Inc. held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting did not reach a quorum as per the company's Amended and Restated Bylaws, with only 331,696 shares represented. Consequently, the meeting was adjourned without conducting any business, to allow more time for stockholders to vote and to achieve the required quorum. The adjourned meeting is scheduled to reconvene virtually on February 7, 2024. The record date for stockholder determination remains November 6, 2023, and those who have already voted do not need to take further action. The company's definitive proxy statement was filed with the SEC on November 20, 2023, and no changes have been made to the proposals since. NexImmune is actively soliciting votes and encourages stockholders to review the proxy statement and vote if they have not already done so. The company also announced that its current cash and cash equivalents are expected to sustain operations through mid-February 2024 and it continues to explore strategic or financing alternatives. As of the record date, NexImmune had 1,058,125 shares of common stock issued and outstanding.
2024年1月18日，NexImmune, Inc.举行了一次股东特别会议，就该公司的清算和解散进行投票。但是，根据公司经修订和重述的章程，会议没有达到法定人数，仅有331,696股股票。因此，会议在没有进行任何事务的情况下休会，以便让股东有更多时间进行投票并达到所需的法定人数。休会后的会议计划于2024年2月7日虚拟地重新召开。股东决定的记录日期仍然是2023年11月6日，已经投票的人无需采取进一步行动。该公司的最终委托书已于2023年11月20日向美国证券交易委员会提交，此后没有对提案进行任何修改。NexImmune正在积极征集选票，并鼓励股东审查委托书，如果尚未这样做，则进行投票。该公司还宣布，其目前的现金和现金等价物预计将持续运营至2024年2月中旬，并将继续探索战略或融资替代方案。截至创纪录的日期，NexImmune已发行和流通了1,058,125股普通股。
2024年1月18日，NexImmune, Inc.举行了一次股东特别会议，就该公司的清算和解散进行投票。但是，根据公司经修订和重述的章程，会议没有达到法定人数，仅有331,696股股票。因此，会议在没有进行任何事务的情况下休会，以便让股东有更多时间进行投票并达到所需的法定人数。休会后的会议计划于2024年2月7日虚拟地重新召开。股东决定的记录日期仍然是2023年11月6日，已经投票的人无需采取进一步行动。该公司的最终委托书已于2023年11月20日向美国证券交易委员会提交，此后没有对提案进行任何修改。NexImmune正在积极征集选票，并鼓励股东审查委托书，如果尚未这样做，则进行投票。该公司还宣布，其目前的现金和现金等价物预计将持续运营至2024年2月中旬，并将继续探索战略或融资替代方案。截至创纪录的日期，NexImmune已发行和流通了1,058,125股普通股。
有用
没用